AZD6094
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AZD6094, covering 2022-06-15 to 2022-06-15. Get the full timeline:
Most recent: Clinical Trial Update: Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment [Phase 2]